# IBI3014

Source: https://onco.cc/drugs/ibi3014/  
OnCo record `ibi3014` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IBI3014 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.

## Summary

AACR 2025 abstract 344 describes a TROP2/PD-L1 bispecific ADC with an NT1 TOP1 inhibitor payload. The abstract reports cell and xenograft activity, stability and monkey toxicology, not clinical efficacy. NCT06974812 separately registers a recruiting phase 1/2 study. A clinical registry entry does not convert the preclinical comparisons into evidence of patient benefit or a validated safety advantage.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-10-06
- Modality: ADC
- Mechanism: Bispecific TROP2/PD-L1 antibody-drug conjugate combining NT1 delivery with immune checkpoint blockade.
- Payload: NT1 (TOP1 inhibitor)

## Sources

- Publisher abstract: https://doi.org/10.1158/1538-7445.am2025-344
- ClinicalTrials.gov NCT06974812: https://clinicaltrials.gov/study/NCT06974812

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Bispecific ADC](https://onco.cc/technologies/bispecific-adc/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/), [TROP2](https://onco.cc/targets/trop2/)
- trials: [IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct06974812/)

---
JSON: https://onco.cc/api/v1/entities/ibi3014.json